Cross-Sector entity
The 159-day window averages about 0.9 stories each week. The busiest single day carried 3. market-trends accounts for 5 of the 20 tracked stories, while 7 other categories carry the remainder. Johnson & Johnson is most often covered alongside Kenvue, which appears in 4 of these 20 stories.
25 verified stories tracked
Last mentioned: Aug 2, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 10 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The 159-day window averages about 0.9 stories each week. The busiest single day carried 3. market-trends accounts for 5 of the 20 tracked stories, while 7 other categories carry the remainder. Johnson & Johnson is most often covered alongside Kenvue, which appears in 4 of these 20 stories. Negative sentiment appears in 25% of the tracked stories. We currently track 20 Cross-Sector stories that mention Johnson & Johnson, published between February 25, 2026 and August 2, 2026. Each carries 2.1 original sources on average.
Computed from the 20 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Johnson & Johnson. Shared-story counts are live from our verified record — not editorial picks.
Data Readout
Anticipated top-line data from the Phase 3 VERIFY clinical trial.
$5.5B Settlement Announced
J&J proposes a global settlement to resolve around 76,000 pending ovarian cancer talc lawsuits, contingent on 95% claimant approval.
Q4 Earnings
Scheduled announcement of quarterly financial results and pipeline update.
BofA Price Target Hike
Bank of America increases price target, highlighting R&D productivity and MedTech growth.
Institutional Rebalancing
Richard Bernstein Advisors and Rathbones Group PLC report reduced holdings in JNJ.
Fast-Track Approval
USFDA grants approval for Tecvayli-Darzalex combination via fast-track voucher program.
12-Month High
JNJ shares reach a new yearly peak following FDA approval for multiple myeloma combo.
Institutional Exit Revealed
13F filings reveal a $170 million divestment by a major institutional fund.
TGA Approval
Australian regulatory body approves the Virtual Nodule Clinic for clinical use.
120% Gain Milestone
PTGX stock reaches a 120% gain milestone from its 52-week low.
J&J Partnership Milestone
Johnson & Johnson advances JNJ-2113 into late-stage trials, validating oral peptide tech.
Pipeline Update
Initial Phase 1 data released for LB2102 in solid tumors at a major medical conference.
120% Rally
Stock price reaches a 12-month peak following sustained clinical momentum.
JNJ-2113 Phase 3 Progress
Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials.
Phase 3 Data Release
Positive Phase 3 data for rusfertide in polycythemia vera triggers initial stock rally.
Manufacturing Expansion
Obelisc facility in Belgium reaches full operational status for clinical and commercial supply.
FY 2025 Earnings
Legend Biotech reports full-year results and commercial highlights.
VERIFY Enrollment
Completion of enrollment for the Phase 3 trial of rusfertide in polycythemia vera.
J&J Partnership Expansion
Johnson & Johnson expands the scope of the oral peptide collaboration.
Phase 2 Success
JNJ-2113 reports positive Phase 2 data in plaque psoriasis, triggering milestone payments.
Colorado’s $12M opioid grant round, awarded to 27 organizations, will bolster youth treatment, prison re-entry support, and a rural behavioral health workforce—key gaps in the state’s healthcare delivery system. The highly competitive process drew 287 applications, highlighting the severe need for prevention infrastructure.
Colorado’s distribution of $12 million to 27 groups from opioid settlement funds is the latest reminder of pharma’s enduring financial and reputational liabilities. The grants, part of a broader $700M+ state settlement, fuel prevention programs while underscoring that litigation costs continue to ripple through the industry.
Source: kjct8.com
The $5.5B proposal to resolve 76,000 ovarian cancer talc lawsuits represents a strategic retreat for J&J, contingent on 95% claimant approval and following failed bankruptcy attempts.
The settlement highlights decades of health concerns over talc's link to ovarian cancer, prompting J&J to switch to cornstarch and underscoring ongoing consumer trust issues.
The settlement removes a major litigation distraction, allowing Johnson & Johnson to redirect resources toward its core pharmaceutical and medtech segments, which generate $85B in annual revenue.
Source: 1190talkradio.iheart.com · manilatimes.net
The legal reinstatement of Tylenol-autism lawsuits pressures healthcare providers to reconcile conflicting evidence on acetaminophen safety in pregnancy, potentially altering clinical guidance, patient counseling, and EHR decision support.
The 2nd Circuit ruling revives mass tort litigation linking prenatal acetaminophen to autism, exposing Kenvue and retailers to billions in potential liability. The decision hinges on admissibility of novel scientific evidence, challenging Daubert standards and regulatory orthodoxy.
Source: fox5atlanta.com · fox32chicago.com
J&J’s Q2 2026 earnings beat underscores a successful pivot away from Stelara’s $10B peak. New oncology and immunology drugs are powering growth, with full-year revenue now expected to top $100B. For healthcare stakeholders, this signals pipeline resilience and a defensive stock offering amid sector headwinds.
Source: The Motley Fool · fool.com
The iShares U.S. Pharmaceuticals ETF (IHE) and iShares Global Healthcare ETF (IXJ) differ in expense ratios (0.39% vs 0.41%), AUM ($1.4B vs $4.1B), and diversification (56 vs 110 holdings). For finance professionals, the 0.02% fee gap may tip the scales for cost-conscious portfolios, but liquidity and global exposure often justify IXJ's slightly higher expense.
Source: Cory Renauer (us) · fool.com
As the market enters March 2026, investors are increasingly turning to 'Dividend Kings'—companies with over 50 consecutive years of dividend increases—as a defensive hedge against lingering volatility. This briefing analyzes the top three picks for the month: Procter & Gamble, Johnson & Johnson, and Coca-Cola, highlighting their resilience and compounding potential.
Source: finance.yahoo.com · fool.com
Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.
Protagonist Therapeutics (PTGX) is scheduled to release its quarterly earnings on Wednesday, March 18, 2026, with investors focused on the commercialization path for rusfertide and the Phase 3 progress of its oral IL-23 receptor antagonist, icotrokinra. The results will provide a critical update on the company's transition from a clinical-stage biotech to a potential commercial powerhouse in the immunology and hematology sectors.
Source: themarketsdaily.com · tickerreport.com
Bank of America has raised its price target for Johnson & Johnson, citing robust growth in the company's pharmaceutical and MedTech pipelines. The upgrade follows a series of FDA approvals and a strategic pivot toward high-margin innovative medicine after the Kenvue spinoff.
Bank of America has raised its price target for Johnson & Johnson, citing a robust outlook for the company's Innovative Medicine and MedTech divisions. The upgrade reflects growing confidence in JNJ's oncology pipeline and its ability to navigate upcoming patent expirations for key assets.
Bank of America has raised its price target for Johnson & Johnson (JNJ), citing a strengthened outlook for the company's pharmaceutical and MedTech pipelines. The upgrade reflects growing investor confidence in JNJ's post-Kenvue strategy, which prioritizes high-margin innovation in oncology, immunology, and surgical robotics.
Source: finance.yahoo.com · insidermonkey.com
A new DelveInsight report projects a steady 7% CAGR for the minimally invasive surgical devices (MISD) market through 2034, driven by technological leaps in robotics and a global shift toward outpatient care. This expansion reflects a broader healthcare transition prioritizing reduced recovery times and improved clinical outcomes over traditional open surgeries.
Source: finanznachrichten.de · prnewswire.com
Legend Biotech and Core Molding Technologies released their full-year 2025 financial results, highlighting a period of strategic expansion and operational resilience. While Legend Biotech continues to scale its CAR-T therapy footprint, Core Molding demonstrated steady performance in the industrial manufacturing sector.
Legend Biotech (LEGN) has announced its fourth-quarter and full-year 2025 financial results, showcasing a significant surge in net trade sales for its CAR-T therapy, Carvykti. The company continues to expand its manufacturing footprint and advance its pipeline in solid tumors, solidifying its position as a leader in the cell therapy market.
Optellum has received regulatory clearance from Australia’s Therapeutic Goods Administration (TGA) for its AI-driven lung nodule management platform. The approval enables the deployment of the Virtual Nodule Clinic to help Australian clinicians identify and treat early-stage lung cancer more effectively.
Protagonist Therapeutics has seen its stock price more than double following clinical breakthroughs in its oral peptide portfolio, yet a major institutional investor has liquidated a $170 million position. This tactical exit highlights the tension between clinical optimism and institutional profit-taking as the company nears critical Phase 3 milestones.
